Latest Breaking News On - Fulvestrant improves - Page 1 : comparemela.com

Inavolisib was submitted to the FDA for review as a first-line treatment for advanced HR-positive, HER2-negative PIK3CA-mutated breast cancer.

Levi garrawayMayne pharma groupMayne pharma group limitedBreakthrough therapy designationPatients with breastPublished decemberPlus palbociclibFulvestrant improvesSystematic reviewDiagnostic workupIntj breastPatients withHormone receptor positiveLocally advancedMetastatic breast cancer